Refractory psoriasis treatment with etanercept
Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis. Twenty two patients with severe and refractory psoriasi...
Gespeichert in:
| Veröffentlicht in: | Medicina clínica 2005-09, Vol.125 (10), p.371-373 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 373 |
|---|---|
| container_issue | 10 |
| container_start_page | 371 |
| container_title | Medicina clínica |
| container_volume | 125 |
| creator | Mahiques Santos, Laura Martínez-Menchón, Teresa Sánchez Carazo, José Luis Pérez-Ferriols, Amparo Soriano Navarro, Carlos Joaquín Fortea Baixauli, José Miguel |
| description | Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis.
Twenty two patients with severe and refractory psoriasis in an open-label clinical trial were studied. Patients received etanercept 50 mg/week subcutaneously during 6 months. PASI (Psoriasis Assessment and Severity Index) was used to monitor disease activity in each month of treatment and in the follow up. Results at weeks 12 and 24 are shown.
96% of patients improved their PASI basal score early at week 12. This improvement was maintained until week 24. Etanercept was well tolerated without any significant adverse reaction. Time until relapse was 2.27 +/- 0.59 months (CI 95%: 1.94-2.60).
Etanercept seems an effective therapy for severe and refractory psoriasis yet long-term dosing and safety studies of etanercept in psoriasic patients are needed. |
| doi_str_mv | 10.1157/13079169 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68624244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68624244</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-8be2639f175a21ac23671ab6a4e1de8192978e00e26b78d95059d737b18c7d463</originalsourceid><addsrcrecordid>eNo1j0tLw0AUhWeh2FoFf4Fk5S517rzuzFKKLygIpa7DJLnBSNLEmQnSf2_Eujoc-Pg4h7Eb4GsAjfcgOTow7owtORc6R9RywS5j_PytEvCCLcCA1VqZJVvvqAm-SkM4ZmMcQutjG7MUyKeeDin7btNHRskfKFQ0pit23vgu0vUpV-z96XG_ecm3b8-vm4dtPoJ0KbclCSNdA6i9AF8JaRB8abwiqMmCEw4tcT5TJdraaa5djRJLsBXWysgVu_vzjmH4miimom9jRV03DxmmWBhrhBJKzeDtCZzKnupiDG3vw7H4fyh_AMy5Tjc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68624244</pqid></control><display><type>article</type><title>Refractory psoriasis treatment with etanercept</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Mahiques Santos, Laura ; Martínez-Menchón, Teresa ; Sánchez Carazo, José Luis ; Pérez-Ferriols, Amparo ; Soriano Navarro, Carlos Joaquín ; Fortea Baixauli, José Miguel</creator><creatorcontrib>Mahiques Santos, Laura ; Martínez-Menchón, Teresa ; Sánchez Carazo, José Luis ; Pérez-Ferriols, Amparo ; Soriano Navarro, Carlos Joaquín ; Fortea Baixauli, José Miguel</creatorcontrib><description>Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis.
Twenty two patients with severe and refractory psoriasis in an open-label clinical trial were studied. Patients received etanercept 50 mg/week subcutaneously during 6 months. PASI (Psoriasis Assessment and Severity Index) was used to monitor disease activity in each month of treatment and in the follow up. Results at weeks 12 and 24 are shown.
96% of patients improved their PASI basal score early at week 12. This improvement was maintained until week 24. Etanercept was well tolerated without any significant adverse reaction. Time until relapse was 2.27 +/- 0.59 months (CI 95%: 1.94-2.60).
Etanercept seems an effective therapy for severe and refractory psoriasis yet long-term dosing and safety studies of etanercept in psoriasic patients are needed.</description><identifier>ISSN: 0025-7753</identifier><identifier>DOI: 10.1157/13079169</identifier><identifier>PMID: 16185546</identifier><language>spa</language><publisher>Spain</publisher><subject>Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Etanercept ; Female ; Humans ; Immunoglobulin G - therapeutic use ; Male ; Middle Aged ; Psoriasis - drug therapy ; Receptors, Tumor Necrosis Factor - therapeutic use</subject><ispartof>Medicina clínica, 2005-09, Vol.125 (10), p.371-373</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16185546$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahiques Santos, Laura</creatorcontrib><creatorcontrib>Martínez-Menchón, Teresa</creatorcontrib><creatorcontrib>Sánchez Carazo, José Luis</creatorcontrib><creatorcontrib>Pérez-Ferriols, Amparo</creatorcontrib><creatorcontrib>Soriano Navarro, Carlos Joaquín</creatorcontrib><creatorcontrib>Fortea Baixauli, José Miguel</creatorcontrib><title>Refractory psoriasis treatment with etanercept</title><title>Medicina clínica</title><addtitle>Med Clin (Barc)</addtitle><description>Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis.
Twenty two patients with severe and refractory psoriasis in an open-label clinical trial were studied. Patients received etanercept 50 mg/week subcutaneously during 6 months. PASI (Psoriasis Assessment and Severity Index) was used to monitor disease activity in each month of treatment and in the follow up. Results at weeks 12 and 24 are shown.
96% of patients improved their PASI basal score early at week 12. This improvement was maintained until week 24. Etanercept was well tolerated without any significant adverse reaction. Time until relapse was 2.27 +/- 0.59 months (CI 95%: 1.94-2.60).
Etanercept seems an effective therapy for severe and refractory psoriasis yet long-term dosing and safety studies of etanercept in psoriasic patients are needed.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psoriasis - drug therapy</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><issn>0025-7753</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLw0AUhWeh2FoFf4Fk5S517rzuzFKKLygIpa7DJLnBSNLEmQnSf2_Eujoc-Pg4h7Eb4GsAjfcgOTow7owtORc6R9RywS5j_PytEvCCLcCA1VqZJVvvqAm-SkM4ZmMcQutjG7MUyKeeDin7btNHRskfKFQ0pit23vgu0vUpV-z96XG_ecm3b8-vm4dtPoJ0KbclCSNdA6i9AF8JaRB8abwiqMmCEw4tcT5TJdraaa5djRJLsBXWysgVu_vzjmH4miimom9jRV03DxmmWBhrhBJKzeDtCZzKnupiDG3vw7H4fyh_AMy5Tjc</recordid><startdate>20050924</startdate><enddate>20050924</enddate><creator>Mahiques Santos, Laura</creator><creator>Martínez-Menchón, Teresa</creator><creator>Sánchez Carazo, José Luis</creator><creator>Pérez-Ferriols, Amparo</creator><creator>Soriano Navarro, Carlos Joaquín</creator><creator>Fortea Baixauli, José Miguel</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20050924</creationdate><title>Refractory psoriasis treatment with etanercept</title><author>Mahiques Santos, Laura ; Martínez-Menchón, Teresa ; Sánchez Carazo, José Luis ; Pérez-Ferriols, Amparo ; Soriano Navarro, Carlos Joaquín ; Fortea Baixauli, José Miguel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-8be2639f175a21ac23671ab6a4e1de8192978e00e26b78d95059d737b18c7d463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psoriasis - drug therapy</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahiques Santos, Laura</creatorcontrib><creatorcontrib>Martínez-Menchón, Teresa</creatorcontrib><creatorcontrib>Sánchez Carazo, José Luis</creatorcontrib><creatorcontrib>Pérez-Ferriols, Amparo</creatorcontrib><creatorcontrib>Soriano Navarro, Carlos Joaquín</creatorcontrib><creatorcontrib>Fortea Baixauli, José Miguel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medicina clínica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahiques Santos, Laura</au><au>Martínez-Menchón, Teresa</au><au>Sánchez Carazo, José Luis</au><au>Pérez-Ferriols, Amparo</au><au>Soriano Navarro, Carlos Joaquín</au><au>Fortea Baixauli, José Miguel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Refractory psoriasis treatment with etanercept</atitle><jtitle>Medicina clínica</jtitle><addtitle>Med Clin (Barc)</addtitle><date>2005-09-24</date><risdate>2005</risdate><volume>125</volume><issue>10</issue><spage>371</spage><epage>373</epage><pages>371-373</pages><issn>0025-7753</issn><abstract>Etanercept is a dimeric fusion protein that binds to tumor necrosis factor and blocks inflammatory response. The purpose of this study was to assess the effects of etanercept and its maintenance in patients with severe and refractory psoriasis.
Twenty two patients with severe and refractory psoriasis in an open-label clinical trial were studied. Patients received etanercept 50 mg/week subcutaneously during 6 months. PASI (Psoriasis Assessment and Severity Index) was used to monitor disease activity in each month of treatment and in the follow up. Results at weeks 12 and 24 are shown.
96% of patients improved their PASI basal score early at week 12. This improvement was maintained until week 24. Etanercept was well tolerated without any significant adverse reaction. Time until relapse was 2.27 +/- 0.59 months (CI 95%: 1.94-2.60).
Etanercept seems an effective therapy for severe and refractory psoriasis yet long-term dosing and safety studies of etanercept in psoriasic patients are needed.</abstract><cop>Spain</cop><pmid>16185546</pmid><doi>10.1157/13079169</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7753 |
| ispartof | Medicina clínica, 2005-09, Vol.125 (10), p.371-373 |
| issn | 0025-7753 |
| language | spa |
| recordid | cdi_proquest_miscellaneous_68624244 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Etanercept Female Humans Immunoglobulin G - therapeutic use Male Middle Aged Psoriasis - drug therapy Receptors, Tumor Necrosis Factor - therapeutic use |
| title | Refractory psoriasis treatment with etanercept |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A38%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Refractory%20psoriasis%20treatment%20with%20etanercept&rft.jtitle=Medicina%20cl%C3%ADnica&rft.au=Mahiques%20Santos,%20Laura&rft.date=2005-09-24&rft.volume=125&rft.issue=10&rft.spage=371&rft.epage=373&rft.pages=371-373&rft.issn=0025-7753&rft_id=info:doi/10.1157/13079169&rft_dat=%3Cproquest_pubme%3E68624244%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68624244&rft_id=info:pmid/16185546&rfr_iscdi=true |